Scholarlink

Background <p>Trophoblast cells are a critical component of retained products of conception (RPOC). While mifepristone is widely used as a non-invasive treatment for RPOC, its precise molecular mechanisms in trophoblast regulation remain poorly defined.</p> Results <p>Through integrated in vitro and in vivo approaches using human trophoblast stem cells (TSCs), HTR8/SVneo cells, and placental villus explants, we demonstrated that mifepristone exerts its effects predominantly via progesterone receptor (PGR) antagonism rather than glucocorticoid receptor (GR) inhibition. PGR knockdown in TSCs and trophoblast organoids impaired trophoblast stemness. RNA-sequencing of PGR-knockdown TSCs revealed upregulated apoptosis and reduced self-renewal and differentiation abilility, identifying PDCD4 as a key downstream target. Functional experiments showed that PDCD4 overexpression recapitulated the mifepristone-induced trophoblast dysfunction, including diminished proliferation, migration, invasion, and stemness, as well as increased apoptosis. In vivo, mifepristone administration in pregnant mice elevated PDCD4 expression, enhanced placental apoptosis, and facilitated clearance of conception products.</p> Conclusions <p>Our findings reveal that mifepristone impairs trophoblast function by antagonizing PGR and inducing PDCD4, thereby impairing stemness and promoting apoptosis. This mechanistic insight not only advances our understanding of mifepristone’s action in RPOC treatment but also suggests broader clinical implications for targeting trophoblast function.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Progesterone receptor antagonism by mifepristone impairs trophoblast stemness and promotes apoptosis through upregulation of PDCD4

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月27日

查看全文
  • Jie Zhou,
  • Li Yan,
  • Yamei Li,
  • Suming Huang,
  • Qicheng Lan,
  • Duo Zhang,
  • Qian Zhu,
  • Xiaoya Zhao,
  • Jian Zhang

摘要

Background

Trophoblast cells are a critical component of retained products of conception (RPOC). While mifepristone is widely used as a non-invasive treatment for RPOC, its precise molecular mechanisms in trophoblast regulation remain poorly defined.

Results

Through integrated in vitro and in vivo approaches using human trophoblast stem cells (TSCs), HTR8/SVneo cells, and placental villus explants, we demonstrated that mifepristone exerts its effects predominantly via progesterone receptor (PGR) antagonism rather than glucocorticoid receptor (GR) inhibition. PGR knockdown in TSCs and trophoblast organoids impaired trophoblast stemness. RNA-sequencing of PGR-knockdown TSCs revealed upregulated apoptosis and reduced self-renewal and differentiation abilility, identifying PDCD4 as a key downstream target. Functional experiments showed that PDCD4 overexpression recapitulated the mifepristone-induced trophoblast dysfunction, including diminished proliferation, migration, invasion, and stemness, as well as increased apoptosis. In vivo, mifepristone administration in pregnant mice elevated PDCD4 expression, enhanced placental apoptosis, and facilitated clearance of conception products.

Conclusions

Our findings reveal that mifepristone impairs trophoblast function by antagonizing PGR and inducing PDCD4, thereby impairing stemness and promoting apoptosis. This mechanistic insight not only advances our understanding of mifepristone’s action in RPOC treatment but also suggests broader clinical implications for targeting trophoblast function.